Cingulate (CINGW) Share-based Compensation (2021 - 2026)
Cingulate's (CINGW) quarterly Share-based Compensation came in at $1.1 million in Q2 2026, up 176.63% on a YoY basis from $398839.0 in Q2 2025, and up 185.86% quarter-over-quarter from $385965.0 in Q4 2025.
Analysis
Cingulate (CINGW) Share-based Compensation (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Share-based Compensation for 6 consecutive years, with $1.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Share-based Compensation rose 176.63% year-over-year to $1.1 million; the trailing twelve-month figure through Jun 2026 stood at $1.1 million (up 176.63% YoY), and the FY2025 full-year result was $1.5 million, up 53.07% from the prior year.
- Share-based Compensation improved to $1.1 million in Q2 2026 per CINGW's latest filing, from $385965.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.6 million in Q2 2024 and bottomed at $60349.0 in Q4 2024.
- Historically, Share-based Compensation has averaged $695478.9 across 5 years, with a median of $812691.0 in 2024.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation tumbled 90.12% in 2022, then soared 539.55% in 2025.
- Over 5 years, Share-based Compensation stood at $206436.0 in 2022, then retreated by 25.13% to $154564.0 in 2023, then sank by 60.96% to $60349.0 in 2024, then jumped by 539.55% to $385965.0 in 2025, then surged by 185.86% to $1.1 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.1 million, $385965.0, and $951677.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.46 Bn | 623.70 Bn | 17.26 Bn | -950.00 Mn |
| 2 | AbbVie | 440.11 Bn | 433.54 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 365.04 Bn | 357.90 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 249.00 Mn |
| 6 | Sanofi | 52.47 Bn | 45.09 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.26 Bn | 44.26 Bn | - | 277.20 Mn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 67.26 Mn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | 19.00 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | 1.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Mn |
| Dec 31, 2025 | 385,965.00 |
| Sep 30, 2025 | 951,677.00 |
| Jun 30, 2025 | 398,839.00 |
| Mar 31, 2025 | 357,649.00 |
| Dec 31, 2024 | 60,349.00 |
| Sep 30, 2024 | 812,691.00 |
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 164,575.00 |
| Dec 31, 2023 | 154,564.00 |
| Sep 30, 2023 | 1.45 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Mar 31, 2023 | 204,479.00 |
| Dec 31, 2022 | 206,436.00 |
| Sep 30, 2022 | 881,112.00 |
| Jun 30, 2022 | 883,801.00 |
| Mar 31, 2022 | 866,284.00 |
| Dec 31, 2021 | 2.09 Mn |